Clinical Characteristics of Moxifloxacin‐Related Arrhythmias and Development of a Predictive Nomogram: A Case Control Study
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.6101 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Peng Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Medical Supplies Center, Chinese People's Liberation Army General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Moxifloxacin, Nomograms, Arrhythmias, Cardiac, Electrocardiography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Key Project Medical Innovation Project in 2017, the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs commissioned by the Chinese Association of Research Hospitals.
Abstract (Originalsprache)
This study aimed to analyze the incidence, clinical characteristics, and risk factors of moxifloxacin‐related arrhythmias and electrocardiographic alterations in hospitalized patients using real‐world data. Concurrently, a nomogram was established and validated to provide a practical tool for prediction. Retrospective automatic monitoring of inpatients using moxifloxacin was performed in a Chinese hospital from January 1, 2017, to December 31, 2021, to obtain the incidence of drug‐induced arrhythmias and electrocardiographic alterations. Propensity score matching was conducted to balance confounders and analyze clinical characteristics. Based on the risk and protective factors identified through logistic regression analysis, a prediction nomogram was developed and internally validated using the Bootstrap method. Arrhythmias and electrocardiographic alterations occurred in 265 of 21,711 cases taking moxifloxacin, with an incidence of 1.2%. Independent risk factors included medication duration (odds ratio [OR] 1.211, 95% confidence interval [CI] 1.156‐1.270), concomitant use of meropenem (OR 4.977, 95% CI 2.568‐9.644), aspartate aminotransferase >40 U/L (OR 3.728, 95% CI 1.800‐7.721), glucose >6.1 mmol/L (OR 2.377, 95% CI 1.531‐3.690), and abnormally elevated level of amino‐terminal brain natriuretic peptide precursor (OR 2.908, 95% CI 1.640‐5.156). Concomitant use of cardioprotective drugs (OR 0.430, 95% CI 0.220‐0.841) was a protective factor. The nomogram showed good differentiation and calibration, with enhanced clinical benefit. The incidence of moxifloxacin‐related arrhythmias and electrocardiographic alterations is in the range of common. The nomogram proves valuable in predicting the risk in the moxifloxacin‐administered population, offering significant clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Medical Supplies Center, Chinese People's Liberation Army General Hospital, Beijing, China.
- Chinese People's Liberation Army Medical School, Beijing, China.
ORCID-Profile: Peng Li, Daihong Guo
Förderung
- Key Project Medical Innovation Project in 2017
- the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs commissioned by the Chinese Association of Research Hospitals
Zitieren
APA
Li, P., Zhu, M., Gao, A., Guo, H., Fu, A., Zhao, A., & Guo, D. (2024). Clinical Characteristics of Moxifloxacin‐Related Arrhythmias and Development of a Predictive Nomogram: A Case Control Study. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6101
Vancouver
Li P, Zhu M, Gao A, Guo H, Fu A, Zhao A, et al. Clinical Characteristics of Moxifloxacin‐Related Arrhythmias and Development of a Predictive Nomogram: A Case Control Study. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.6101
BibTeX
@article{Li2024,
author = {Li, Peng and Zhu, Man and Gao, Ao and Guo, Haili and Fu, An and Zhao, Anqi and Guo, Daihong},
title = {Clinical Characteristics of Moxifloxacin‐Related Arrhythmias and Development of a Predictive Nomogram: A Case Control Study},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.6101}
}
EUVIMED